Brief: SomaLogic Inc - Full Year 2023 Revenue Guidance Of $80 Million-$84 Million
28/03/2023 23:35
March 28 (Reuters) - Somalogic Inc SLGC.O :
* SOMALOGIC REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS, ANNOUNCES DIRECTOR APPOINTMENTS AND MANAGEMENT
EVOLUTION
* ADAM TAICH, EVP LIFE SCIENCES, PROMOTED TO INTERIM CEO
WITH A
FOCUS ON OPERATIONAL EXECUTION
* FULL YEAR 2023 REVENUE GUIDANCE OF $80 MILLION-$84 MILLION
* Q4 2022 REVENUE OF $18.8 MILLION
* ROY SMYTHE, HAS STEPPED DOWN FROM HIS ROLE AS CHIEF
EXECUTIVE
OFFICER AND BOARD MEMBER, ALSO EFFECTIVE TODAY
* NET LOSS WAS $49.3 MILLION IN Q4 OF 2022, OR A LOSS OF
$0.26 PER
SHARE
* Q4 REVENUE VIEW $16.6 MILLION -- REFINITIV IBES DATA
* FY2023 REVENUE VIEW $92.8 MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX1zZmZZ
Further company coverage: SLGC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Somalogic
See all newsBrief: Somalogic Stockholders Vote To Approve Standard Biotools Transaction At Special Meeting
Brief: Madryn Asset Management Demands Somalogic’S Board Address Repeated, Unprecedented Adjournments Of Tainted Special Meeting
Brief: Madryn Asset Management Says It Urges All Somalogic Shareholders To Oppose Transaction With Standard Biotools
Brief: Madryn Asset Management Urges Shareholders To Vote “Against” The Proposed Merger And Allow Somalogic To Pursue Value-Enhancing Alternatives
Brief: Somalogic Board Reiterates Value-Maximizing Transaction With Standard Biotools Is In Best Interests Of All Stockholders